KR20030028638A - Method of producing a Healthy Mulberry Leaf Food by culture of Mushroom Mycelia - Google Patents
Method of producing a Healthy Mulberry Leaf Food by culture of Mushroom Mycelia Download PDFInfo
- Publication number
- KR20030028638A KR20030028638A KR1020010058344A KR20010058344A KR20030028638A KR 20030028638 A KR20030028638 A KR 20030028638A KR 1020010058344 A KR1020010058344 A KR 1020010058344A KR 20010058344 A KR20010058344 A KR 20010058344A KR 20030028638 A KR20030028638 A KR 20030028638A
- Authority
- KR
- South Korea
- Prior art keywords
- mulberry leaf
- culture
- mushroom mycelium
- mushroom
- powder
- Prior art date
Links
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 8
- 235000013305 food Nutrition 0.000 title abstract description 6
- 240000000249 Morus alba Species 0.000 claims abstract description 47
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 17
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 16
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 16
- 241000001727 Tropicoporus linteus Species 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 6
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 5
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 238000012258 culturing Methods 0.000 claims abstract description 5
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 239000013028 medium composition Substances 0.000 claims description 17
- 241000222518 Agaricus Species 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 239000001965 potato dextrose agar Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 229920002498 Beta-glucan Polymers 0.000 claims description 4
- 210000003056 antler Anatomy 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 4
- 241000255789 Bombyx mori Species 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 229940029982 garlic powder Drugs 0.000 claims description 3
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 240000008415 Lactuca sativa Species 0.000 claims description 2
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 235000019462 natural additive Nutrition 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 238000011218 seed culture Methods 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 239000010902 straw Substances 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims 2
- 241000282994 Cervidae Species 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 238000005520 cutting process Methods 0.000 claims 1
- 238000009837 dry grinding Methods 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 abstract description 7
- 235000019634 flavors Nutrition 0.000 abstract description 7
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- 241001327634 Agaricus blazei Species 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 235000010333 potassium nitrate Nutrition 0.000 abstract 1
- 239000004323 potassium nitrate Substances 0.000 abstract 1
- 230000009471 action Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001647056 Phellinus hartigii Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 235000013666 improved nutrition Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- -1 methylpentose Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
본 발명은 버섯 균사체 배양에 의한 기능성 "버섯 균사체 배양 뽕잎 건강식품"의 제조방법에 관한 것으로, 더욱 상세하게는 뽕잎 또는 건조뽕잎에서 항암작용 있는 영지(Ganoderma lucidum), 상황(Phellinus linteus), 아가리쿠스(Agaricus blazeimurill)등의 버섯 균사체를 배양함으로서 뽕잎의 청취를 제거하고 풍미를 개선하며, 뽕잎조직의 거친 섬유를 분해하고, 생성된 버섯 균사체중의 생리활성물질에 의한 기능성을 강화하여, 풍미가 좋고 건강효과가 우수한 기능성 "버섯 균사체 배양 뽕잎 건강식품"의 제조방법에 관한 것이다.The present invention relates to a method for producing a functional "mushroom mycelium culture mulberry leaf health food" by mushroom mycelium culture, and more specifically, Ganoderma lucidum , situation ( Phellinus linteus ), Agaricus ( By cultivating mushroom mycelium such as Agaricus blazeimurill ), it removes mulberry leaves and improves flavor, decomposes coarse fibers of mulberry leaf tissue, and enhances the functionality by bioactive substances in the produced mushroom mycelium. It relates to a method of producing a functional "mushroom mycelium culture mulberry leaf health food" excellent effect.
버섯류는 분류학상의 진균문, 담자균아문에 속하며 AD 600년에 중국에서 목이버섯(Auricularia auricula)을 세계최초로 재배하였으며 영지속의 버섯은 AD 1621년에 재배하기 시작하였다. 버섯은 옛날부터 특별한 식량으로 간주하여 중국인들은 불로장수약으로, Mexico인디언들은 종교행사와 마술에서 환각제 및 치료제로, Greece인들은 전쟁터에서 무사들의 체력증진의 목적으로, Rome에서는 신의 음식으로 간주하여 특별한 행사 때만 먹을 수 있었다고 한다.The mushrooms belong to the taxonomic and fungal genus of the taxonomy. In the year 600 AD, Auricularia auricula was cultivated in China, and the perennial mushrooms were cultivated in AD 1621. Mushrooms have been regarded as a special food since ancient times, and the Chinese are regarded as a fire treat, the Mexican Indians as hallucinations and remedies in religious events and magic, the Greeks as a god food in the battlefield, and as a god food in Rome. It was said that they could only eat at the event.
영양적 특성을 살펴보면 건물중량으로 탄수화물이 46.6∼82.8%이며, Pentose, methylpentose, hexose, disaccharide, 아미노당, 당 alcohol, 당산도 존재하고 있다. 단백질은 17∼35%를 차지하며 이 중에는 필수아미노산이 고르게 함유되어 있다. 또한 핵산은 2.7∼4.1%를 함유하고 있고 Vitamin등도 고르게 분포하고 있다. 1차적 기능을 하고 있는 영양성분 이외에 3차기능을 하는 다양한 생리활성 물질을 함유하고 있다. 일반적으로 버섯류가 나타내는 생리활성 작용으로는 생체 방어작용, 생체항상성의 유지, 생체리듬의 조절, 질병회복능력과 암이나 뇌졸증, 심장병 등의 성인병에 대한 예방효과가 높이 평가되고 있다. 버섯유래의 약리작용을 나타내는 활성성분은 평균분자량이 100∼2000KD 정도의 단백다당체를 중심으로 하는 고분자물질과 핵산 복합체, terpenoid, steroid, germanium등의 저분자물질로 대별할 수 있다.In terms of nutritional properties, carbohydrate is 46.6-82.8% by dry weight, and Pentose, methylpentose, hexose, disaccharide, amino sugar, sugar alcohol and sugar acid are also present. Protein accounts for 17-35%, evenly containing essential amino acids. Nucleic acid contains 2.7-4.1% and evenly distributes vitamins. In addition to the nutrients that have a primary function, it contains a variety of bioactive substances that have a tertiary function. In general, the physiological activity exhibited by mushrooms is highly evaluated for biological defense, maintenance of bio-alwaysness, regulation of biorhythms, disease recovery ability and preventive effects against adult diseases such as cancer, stroke and heart disease. Active ingredients exhibiting pharmacological activity derived from mushrooms can be roughly classified into high molecular weight compounds with an average molecular weight of 100-2000 KD and low molecular weight substances such as nucleic acid complexes, terpenoids, steroids and germanium.
다당류는 세포내성 다당류(Intracelluar polysaccharide), 세포벽성 다당류, 세포외성 다당류(Extracellular polysaccharide)로 구분하며 이들 단백다당류의 구조적 특성에 따라서 독특한 생리활성을 나타낸다. 고분자 물질인 다당류에 대한 지금까지의 약리작용에 관한 연구 보고에 의하면 버섯은 항암작용(Antibiotic activity), 항균효과(Antiviral effect), 혈당강화효과(Hypoglycemic activity), cholesterol의 저하효과, 항혈전효과를 나타낸다고 한다.Polysaccharides are classified into Intracelluar polysaccharides, cell wall polysaccharides, and extracellular polysaccharides, and exhibit unique biological activities depending on the structural properties of these protein polysaccharides. According to the research reports on the pharmacological action of the polysaccharides, the mushrooms have anti-cancer activity, antiviral effect, hyperglycemic activity, cholesterol lowering effect and antithrombotic effect. It is indicated.
또한 항염증작용, 히스타민 유리억제작용, 간보호작용, 항산화작용, 정력증강작용, 혈소판응집억제작용, 노화억제작용, 방사선보호작용, 중금속제거작용, 신경세포 성장인자 합성촉진작용 등의 생리활성작용도 있다고 한다. 또한 AIDSVirus의 억제작용(영지버섯)도 보고되어 있다. 특히 영지(Ganoderma lucidum), 상황버섯(Phellinus linteus, Phellinus hartigii), 아가리쿠스 버섯(Agaricus blazeimurill)은 항암활성과 성인병을 예방치유하는 여러 가지 생리활성 작용이 있어서 부가가치가 높은 생물산업의 신소재로서 큰 관심을 일으키고 있다. 최근엔 버섯균사체를 액체배양하여 균사체를 식품으로 이용하거나 유용물질을 생산하기 위한 산업적 응용에 목적을 두고 활발하게 연구가 진행되고 있다.In addition, physiological activities such as anti-inflammatory action, histamine free inhibition action, hepatoprotective action, antioxidant action, energetic enhancement action, platelet aggregation inhibitory action, aging inhibitory action, radiation protection action, heavy metal removal action, neuronal growth factor synthesis promoting action It is also said. In addition, the inhibition of AIDSVirus (Ganoderma lucidum) has been reported. In particular, Ganoderma lucidum , Phellinus linteus, Phellinus hartigii , and Agaricus blazeimurill are particularly important as new materials in the high value-added bio-industry because they have various physiological activities that prevent and cure adult diseases. It's happening. Recently, research has been actively conducted for the purpose of industrial application for liquid mycelium mycelium culture to use mycelium as food or to produce useful materials.
종래의 버섯균사체의 생산방법은 발효조(Jar Fermentor)를 이용하여 합성액체배지에서 생산하는 것이었으며 액체로부터 균사체만 분리하여 제약이나 건강식품에 사용하였다. 그러나 합성액체배지를 만드는 각각의 배지는 거의 대부분이 수입품이고 고가이므로 버섯균사체의 생산원가가 대단히 높은 것이 문제이다.Conventional mushroom mycelium production method was produced in a synthetic liquid medium by using a fermentor (Jar Fermentor) and was used for pharmaceutical or health food by separating only the mycelium from the liquid. However, the production cost of mushroom mycelium is a problem because almost all of the medium for making the synthetic liquid medium is imported and expensive.
본 발명의 목적은 영양성분과 생리활성물질을 다량고르게 함유하고 있어 기능성 신생물 소재로 부각되고 있는 뽕잎에서 버섯균사체를 배양하여 뽕잎의 청취를 제거하고 풍미를 개선하며 뽕잎 조직을 분해하는 동시에 단시간내에 각종 영양성분과 생리활성물질을 다량함유하고 있는 버섯균사체를 생산하여 기능성을 향상시킨 기능성 "버섯균사체 배양 뽕잎 건강식품"을 제공하는데 있다.An object of the present invention is to cultivate mushroom mycelium in mulberry leaves that are featured as functional neoplasia material containing a large amount of nutrients and physiologically active substances to remove the listening of mulberry leaves, improve flavor and decompose mulberry leaf tissue in a short time To provide a functional "mushroom mycelium culture mulberry leaf health food" with improved functionality by producing mushroom mycelium containing a large amount of various nutrients and biologically active substances.
그리고 버섯재배농가에서 처럼 버섯자실체(갓모양의 버섯)를 생산하는 것은 기간이 오래 걸리고 버섯자실체의 생산에만 목적을두고 있으나 본발명에서는 버섯균사체의 생산과 버섯균사체의 작용에 의해 청취를 제거하여 풍미를 개선하고, 새로운 유용물질과 각종 유용한 효소를 생합성하며, 거친섬유와 고분자 영양성분을가수분해하여 영양성, 기능성, 기호성이 향상된 균사체 배양 뽕잎을 생산한다음 버섯 균사체와 버섯 균사체를 배양한 뽕잎을 모두 사용하여 "버섯균사체 배양 뽕잎 건강식품의 제조방법"을 제공하는데 목적을 두고 있다.And as in the mushroom cultivation farms, producing mushroom fruiting bodies (fresh mushrooms) takes a long time and aims only at the production of mushroom fruiting bodies. However, in the present invention, the production of mushroom mycelium and the action of mushroom mycelium are used to remove flavors. It improves, biosynthesizes new useful substances and various useful enzymes, and hydrolyzes coarse fiber and macromolecular nutrients to produce mycelium cultured mulberry leaves with improved nutrition, functionality, and palatability. To provide a "method of mushroom fungus cultured mulberry leaf health food".
상기의 목적을 달성하기 위해, 본 발명은, 생뽕잎은 수세, 자연건조후 분쇄기로 직경이 1∼3mm되게 조분쇄하여 조분쇄 뽕잎가루를 얻고, 서목태콩은 같은 중량의 물을 가하여 완전히 팽윤(Soaking)시킨 다음 압력솥(autoclave)을 이용하여 115℃에서 30분간 열처리 한 다음 건조분말화한 후 콩 껍질을 체로 screening하여 제거하여 서목태 콩가루를 얻는다.In order to achieve the above object, the present invention, the raw mulberry leaves are crushed to 1 ~ 3mm in diameter with a pulverizer after washing with water, natural drying to obtain a coarsely pulverized mulberry leaf powder, seomoktae swelling by adding water of the same weight ( After soaking, heat-treat at 115 ℃ using autoclave for 30 minutes, dry powderize and screening and remove soybean hulls to obtain Seomoktae soy flour.
감자는 1cm두께로 잘라 압력솥(autoclave)을 이용하여 115℃에서 30분 호화시킨다음 건조분말화하여 감자가루를 얻는다.Potatoes are cut to 1 cm in thickness and calcined at 115 ° C. for 30 minutes using an autoclave and dried to obtain potato powder.
이상에서 언급한바와 같은 전처리과정을거쳐 얻어진 조분쇄 뽕잎가루 70%(W/W), 서목태콩가루 14%(W/W), 감자가루 5.0%(W/W) 중량부에 미강 5.0%(W/W), 포도당(Glucose) 5.0%(W/W), 질산칼륨(KNO3) 0.5%, 탄산칼슘(caco3) 0.5%(W/W) 중량부를 첨가 균일 혼합한 다음, 물을 중량비로 1.5배 가수하여 버섯균사체 배양용 뽕잎 배지 (medium)조성물을 제조하는 단계 (S1);70% (W / W) of coarsely ground mulberry leaf powder obtained through the pretreatment as mentioned above, 14% (W / W) of Seomok Taekong powder, 5.0% (W / W) of potato powder / W), glucose (Glucose) 5.0% (W / W), potassium nitrate (KNO3) 0.5%, calcium carbonate (caco3) 0.5% (W / W) parts by weight is added and uniformly mixed, water is 1.5 times by weight Hydrolyzing to prepare a mulberry leaf medium (medium) composition for culturing mushroom mycelia (S1);
그리고, 상기(S1)단계에서 제조한 버섯균사체 배양용 뽕잎배지 조성물에 오염된 호기성 부패 미생물의 생육을 억제시키고 영지(Ganoderma lucidum), 상황(Phellinus linteus), 아가리쿠스(Agaricus blazeimurill) 버섯균사체의 생육최적 PH인 5.5∼6.0으로 PH를 낮추기 위해 상기(S1)단계에서 얻어진 버섯균사체 배양용 뽕잎 배지 조성물을 버섯 배양병에 넣고 병의 뚜껑을 파라필름(PARA FILM, American National Can, com)으로 완전 밀봉하여 혐기적 조건으로 만든다음, 30℃로 48시간 Incubation하여 버섯균사체 배양용 뽕잎배지 조성물에 오염된 유용한 야생(wilde Type)의 혐기성 젖산균류, 프로피온산균류, 효모균만을 증식시켜 유기산류(젖산, 프로피온산)를 생성하는 자연발효단계(S2);In addition, it inhibits the growth of aerobic decaying microorganisms contaminated with the mulberry leaf medium composition for mushroom mycelium culture prepared in the step (S1) and Ganoderma lucidum , Phellinus linteus , Agaricus blazeimurill In order to lower the pH to 5.5 to 6.0, which is PH, the mulberry leaf medium composition for mushroom mycelium culture obtained in the step (S1) was put in a mushroom culture bottle, and the bottle cap was completely sealed with parafilm (PARA FILM, American National Can, com). After making an anaerobic condition, the organic acid (lactic acid, propionic acid) is grown by proliferating only useful wild type anaerobic lactic acid bacteria, propionic acid bacteria and yeasts contaminated with mulberry leaf medium composition for mushroom mycelium culture by incubating at 30 ℃ for 48 hours. Natural fermentation step (S2) to produce;
그리고, 상기단계(S2)에서 얻어진 자연발효 버섯균사체 배양용 뽕잎배지 조성물에서 배양할 영지(Ganoderma lucidum), 상황(Phellinus linteus), 아가리쿠스(Agaricus blazeimurill) 버섯균사체를 PDA(Potato Dextrose Agar) 평판 배지에서 20∼28℃로 10일간 각각 배양한 후 생육한 원형의 균사체를 직경 8mm의 Stainless Steel Pipe로 무균적으로 절취하여 균사체 디스크(mycelium disk)를 만든 다음, 각각의 균사체 디스크(Disk) 5∼6개를 PDB(Potato Dextrose Broth) 액체 배지 50mL를 넣은 250mL 삼각 플라스크에 접종하여 20∼28℃에서 7∼10일간 호기적 조건하에서 진탕 배양한 후 얻어진 각각의 균사체 배양액 0.25mL[5%(V/V)]를 다시 새 PDB액체배지 50mL를 함유하는 250mL 삼각 플라스크에 접종하여 20∼28℃에서 7일동안 호기적 조건하에서 진탕 배양하여 활성을 강화시킨 접종용 균사체 종균 배양액을 제조하는 단계(S3); 그리고 상기(S2) 단계의 자연발효에 의해 호기성 부패미생물의 생육이 억제되고 PH가 버섯균사체의 생육 최적 PH인 5.5 ∼6.0으로 저하된 자연발효 버섯균사체 배양용 뽕잎배지 조성물에 상기(S3)단계에서 얻은 영지(Ganoderma lucidum), 상황(Phellinus linteus), 아가리쿠스(Agaricus blazeimurill) 균사체 종균배양액을 각각 5%(V/V)씩 접종하여 온도 20∼28℃, 습도70∼90%에서 45∼60일간 배양하여 버섯균사체를 증식시키는단계(S4); 그리고 상기(S4)단계의 결과 물로 얻은 영지, 상황 또는 아가리쿠스 버섯균사체를 배양한 뽕잎 배지 조성물을 균질화하여 여기에 상백피(뽕나무 뿌리 껍질) 열수 추출액, 인삼가루, 녹용가루, 증숙 건조 마늘가루, 견사(silk)가수분해물, 동충하초, 누에가루, 펙틴, 베타-글루칸(β-D-Glucan)등의 기능성 천연첨가물을 첨가혼합하여 과립, 정제(Tablet), 캅셀(capsule)형태로 제품화하는 단계(S5); 를 포함하는 것을 특징으로 하는 기능성 "버섯균사체 배양 뽕잎 건강식품"의 제조방법을 제공한다. 그리고 이와는 달리,In addition, Ganoderma lucidum , Situary (P hellinus linteus ), Agaricus blazeimurill mushroom mycelium to be cultured in the mulberry leaf medium composition for culturing the natural fermented mushroom mycelium obtained in the step (S2) flat plate PDA (Potato Dextrose Agar) After incubation at 20-28 ° C. for 10 days, the rounded mycelium was aseptically cut into 8 mm diameter Stainless Steel Pipe to make mycelium disk, and then each of the mycelium disk 5-6 Dogs were inoculated into a 250 mL Erlenmeyer flask containing 50 mL of PDB (Potato Dextrose Broth) liquid medium and shaken at 20 to 28 ° C for 7 to 10 days under aerobic conditions. )] Was inoculated again into a 250 mL Erlenmeyer flask containing 50 mL of fresh PDB liquid medium and shaken-cultured under aerobic conditions for 7 days at 20 to 28 ° C. to prepare a mycelial seed culture medium for enhanced activity. The step (S3); And the growth of aerobic decay microorganisms by the natural fermentation of the step (S2) is inhibited and the pH is lowered to 5.5 ~ 6.0, which is the optimal growth of the mushroom mycelium, in the mulberry leaf medium composition for culturing the natural fermented mushroom mycelium in the step (S3) Inoculate 5% (V / V) of the Ganoderma lucidum , Sickle ( Phellinus linteus ), and Agaricus blazeimurill mycelium spawn culture medium at 45-60 days at 20-28 ℃ and 70-90% humidity. Multiplying the mushroom mycelium (S4); And homogenizing the mulberry leaf medium composition cultured Ganoderma lucidum, Sichuan or Agaricus mushroom mycelium obtained as a result of the step (S4) step here, the extract of hot water extract (mulberry root bark) hot water, ginseng powder, antler powder, steamed dried garlic powder, silk thread ( silk) hydrolyzate, Cordyceps sinensis, silkworm powder, pectin, beta-glucan (β-D-Glucan) by adding and mixing functional natural additives in the form of granules, tablets, capsules (S5) ; It provides a method for producing a functional "mushroom mycelium culture mulberry leaf health food" comprising a. And in contrast,
상기(S4) 단계에서 결과물로 얻은 영지, 상황 또는 아가리쿠스 균사체 배양 뽕잎 배지 조성물을 -40℃∼-20℃이하에서 동결 저장하여 빙결정 생성과정에 의해 뽕잎조직과 배양한 버섯균사체의 조직을 파괴시켜 유용성분의 추출이 용이하도록한 다음, 5∼10℃에서 완만해동한 후 유용성분의 파괴를 방지하기 위해 70℃이하의 온수를 중량비로 5배 가한 다음 균질기(Homogenizer)로 균질화 시킨 후 여과하여 여액을 얻고 다시 같은방식으로 3회이상 70℃이하의 온수를 가하여 균질화, 여과 과정을 거쳐 버섯균사체 배양 뽕잎 배지 조성물의 수 추출 액을 얻는 단계(S6); 그리고,Ganoderma lucidum, agar or agaricus mycelium cultured mulberry leaf culture medium obtained as a result in the step (S4) by freezing storage at -40 ℃ ~ -20 ℃ below to destroy the mulberry leaf tissue and the culture of the mushroom mycelium cultured by the ice crystal production process To facilitate the extraction of useful components, gently thaw at 5 to 10 ℃, and then to prevent the destruction of useful components, hot water below 70 ℃ is added five times in weight ratio, homogenized with homogenizer and filtered. Obtaining the filtrate and adding hot water at 70 ° C. or less three times in the same manner to obtain a water extract of the mushroom mycelium culture mulberry leaf medium composition through homogenization and filtration (S6); And,
상기(S6)의 단계에서 얻어진 버섯균사체 배양 뽕잎 배지 조성물의 수 추출액에 사과 농축액, 상백피 열수 추출액, 밀짚 열수 추출액, 녹용 엑기스, 인삼엑기스, 올리고당, 자알리톨등을 첨가하여 캔(Can), 또는 드링크병 형태의 음료로 제품화하는 단계(S7);를 포함하는 것을 특징으로 하는 기능성 "버섯균사체 배양 뽕잎건강식품의 제조방법"을 제공한다.Can (Can), or drink by adding an apple concentrate, lettuce extract hot water extract, straw hot water extract, antler extract, ginseng extract, oligosaccharide, jaalitol, etc. to the water extract of the mushroom mycelium culture mulberry leaf medium composition obtained in the step (S6) It provides a functional "method of mushroom fungus cultured mulberry leaf health food", characterized in that it comprises a step (S7) of the product in the form of a beverage drink.
이상에서 언급한바와 같이, 본 발명에 의해서 만들어지는 과립, 정제(Tablet), 캅셀(capsule)형태와 음료형태의 기능성 버섯균사체 배양 뽕잎 건강식품은 청취가 없고 버섯특유의 향이 생성되어 풍미가 개선되었고, 버섯균사체가 생성하는 가수분해 효소에 의해 고분자 영양물질이 분해되어 소화흡수성이 증가 되었으며, 뽕잎중의 유용성분과 버섯균사체중의 유용성분이 통합되어 더욱 기능성이 강화되었으므로 다음과 같은 건강효과를 기대할 수 있다.As mentioned above, the functional fungus mycelium culture mulberry leaf health food in the form of granules, tablets, capsules and beverages produced by the present invention has no audible and flavors are improved by producing mushroom-specific flavor. , The digestive absorbency was increased by hydrolyzing the polymer nutrients by the hydrolysis enzyme produced by the mushroom mycelium, and the functionalities were enhanced by incorporating the useful components in the mulberry leaves and the useful components in the mushroom mycelium. .
즉 뽕잎중의 생리활성물질들의 작용에 의한 항암작용, cholesterol저하, 지질대사 개선작용, 체지방억제작용(비만억제), 간비대, 지방간억제, 혈전생성억제, 혈당In other words, anti-cancer activity, cholesterol lowering, lipid metabolism improvement, body fat suppression (obesity inhibition), liver hypertrophy, fatty liver inhibition, thrombogenic inhibition, blood sugar by the action of bioactive substances in mulberry leaves
강하작용, 노화억제, 혈압강하작용, 골다공증억제, 숙취해소작용등을 기대할 수 있고, 또한 버섯균사체 등의 생리활성물질의 작용에 의한 항암작용, 항균작용, 혈당강화작용, cholesterol저하 효과, 항혈전 효과, 간보호작용, 항산화 작용, 노화억제 작용, 중금속 제거 작용, 정력증강작용, 신경세포 성장인자 합성촉진작용등을 기대 할 수 있다.Lowering effect, anti-aging, lowering blood pressure, anti-osteoporosis, hangover can be expected, and also anticancer action, antibacterial action, blood sugar strengthening effect, cholesterol lowering effect, antithrombosis by action of bioactive substances such as mushroom mycelium Effects, hepatoprotective action, antioxidant action, anti-aging action, heavy metal removal action, energetic enhancement action, neuronal growth factor synthesis promoting action can be expected.
그리고 서목태콩등의 생리활성물질의 작용에 의한 혈당강화작용, 항암작용(전립선암, 유방암), 갱년기 장애(골다공증, 질건조증)억제작용 콩사포닌에 의한 비만개선, 알코올성 간경변 예방, 숙취해소등을 기대할 수 있다.In addition, blood sugar strengthening, anti-cancer (prostate cancer, breast cancer), menopausal disorders (osteoporosis, vaginal dryness) inhibition by the action of physiologically active substances such as Seomok Tae-kong, soybean saponin to improve obesity, prevent alcoholic cirrhosis, hangover You can expect
그리고 버섯균사체 배양 뽕잎 배지 조성물을 이용하여 제품화하기 전에 기능성을 더욱 강화하기 위해 첨가하는 상백피는 그의 생리활성물질의 작용에 의한 체지방 억제작용, 이뇨작용, 변통작용등에 의해 비만억제작용과 전립선비대 억제작용등을 기대할 수 있고, 누에 가루에 의한 혈당강화작용과 견사(Silk)가수분해물에 의한 정력증강작용을 기대할 수 있다. 그리고 증숙 건조 마늘가루의 생리활성작용에 의한 항암작용, 심장병예방, 혈전예방과 혈류개선 효과를 기대할 수 있다.In addition, the baekbaekpi added to further enhance the functionality before commercialization using the mushroom mycelium culture mulberry leaf medium composition is inhibited by obesity and prostatic hypertrophy by body fat inhibitory action, diuretic action, constipation action by the action of its bioactive substances It can be expected, such as blood sugar strengthening effect by silkworm powder and vibratory potentiation effect by silk hydrolyzate can be expected. And anti-cancer effect, heart disease prevention, thrombus prevention and blood flow improvement effect by the physiological activity of steamed dried garlic powder can be expected.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010058344A KR100844980B1 (en) | 2001-09-20 | 2001-09-20 | Method of producing a Healthy Mulberry Leaf Food by culture of Mushroom Mycelia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010058344A KR100844980B1 (en) | 2001-09-20 | 2001-09-20 | Method of producing a Healthy Mulberry Leaf Food by culture of Mushroom Mycelia |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030028638A true KR20030028638A (en) | 2003-04-10 |
KR100844980B1 KR100844980B1 (en) | 2008-07-09 |
Family
ID=29562083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010058344A KR100844980B1 (en) | 2001-09-20 | 2001-09-20 | Method of producing a Healthy Mulberry Leaf Food by culture of Mushroom Mycelia |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100844980B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020019490A (en) * | 2002-01-21 | 2002-03-12 | 전병태 | The production method and compound(VEL-GLUCAN) of velvet antler containing mushroom mycelium. |
KR20030073720A (en) * | 2002-03-13 | 2003-09-19 | (주)엔앤에스코리아 | The health-assisting food using Phellinus linteus as main materials and its preparation method |
KR100934348B1 (en) * | 2007-11-15 | 2009-12-31 | 전현철 | Camellia leaf or Blossom relief composition and its manufacturing method |
KR101013527B1 (en) * | 2008-04-28 | 2011-02-10 | (주)휴럼 | Ogapy[Acanthopanax]-mushroom mycelium fermentation products for preventing or treating gastrointestinal disease and Pharmaceutic uses thereof extract |
CN102363749A (en) * | 2011-10-09 | 2012-02-29 | 东北林业大学 | Preparation method of Phellinus linteus mycelium |
CN103584074A (en) * | 2013-11-17 | 2014-02-19 | 哈尔滨艾克尔食品科技有限公司 | Ganoderma lucidum chewable tablet |
WO2019177221A1 (en) * | 2018-03-13 | 2019-09-19 | 주식회사 기운찬 | Method for co-culturing inonotus obliquus, ganoderma lucidum, and phellinus linteus mycelia |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101739447B1 (en) | 2015-09-17 | 2017-05-24 | 조혜자 | A powdered-food using low moisture, low temperature and processing method of it |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100335996B1 (en) * | 1999-06-28 | 2002-05-08 | 류인덕 | Method of producing a malberryleaf health food by fermentation of lactic acid bacteria and yeast |
KR100432360B1 (en) * | 2001-03-13 | 2004-05-20 | 에이치엔엠바이오(주) | Method for solid culturing of hyphostroma and carpophore of hericicum erinaceus using a medicinal plant and food to help health including abstract of hyphostroma and carpophore |
KR20010100061A (en) * | 2001-08-18 | 2001-11-14 | -- | Manufacturing method of mulberry extract and liquid beverage containing this |
-
2001
- 2001-09-20 KR KR1020010058344A patent/KR100844980B1/en not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020019490A (en) * | 2002-01-21 | 2002-03-12 | 전병태 | The production method and compound(VEL-GLUCAN) of velvet antler containing mushroom mycelium. |
KR20030073720A (en) * | 2002-03-13 | 2003-09-19 | (주)엔앤에스코리아 | The health-assisting food using Phellinus linteus as main materials and its preparation method |
KR100934348B1 (en) * | 2007-11-15 | 2009-12-31 | 전현철 | Camellia leaf or Blossom relief composition and its manufacturing method |
KR101013527B1 (en) * | 2008-04-28 | 2011-02-10 | (주)휴럼 | Ogapy[Acanthopanax]-mushroom mycelium fermentation products for preventing or treating gastrointestinal disease and Pharmaceutic uses thereof extract |
CN102363749A (en) * | 2011-10-09 | 2012-02-29 | 东北林业大学 | Preparation method of Phellinus linteus mycelium |
CN103584074A (en) * | 2013-11-17 | 2014-02-19 | 哈尔滨艾克尔食品科技有限公司 | Ganoderma lucidum chewable tablet |
WO2019177221A1 (en) * | 2018-03-13 | 2019-09-19 | 주식회사 기운찬 | Method for co-culturing inonotus obliquus, ganoderma lucidum, and phellinus linteus mycelia |
US11503847B2 (en) | 2018-03-13 | 2022-11-22 | Giunchan Co., Ltd. | Method for co-culturing Inonotus obliquus, Ganoderma lucidum, and Phellinus linteus mycelia |
Also Published As
Publication number | Publication date |
---|---|
KR100844980B1 (en) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108260808B (en) | Noni enzyme and preparation method thereof | |
CN101760478B (en) | Preparation method of radix puerariae red yeast rice | |
KR100971677B1 (en) | Method of producing fermentation of herbal medicine, the fermentation produced thereby, and food comprising the fermentation | |
CN103156052A (en) | Submerged fermentation technology of producing immunological enhancement active materials of inonotus obliquus | |
CN101451096A (en) | Method for preparing Chinese caterpillar fungus health wine | |
KR20110104278A (en) | Manufacturing method of fermented materials using wax gourd and functional food of thereof manufacturing | |
CN102994305B (en) | Method for preparing health-care food (therapy) product (nutrient juice wine) by use of extracts from cordyceps militaris and cocoon | |
CN107488598B (en) | Burdock-based cordyceps militaris mycelium and preparation method thereof | |
CN104770731A (en) | Cynomorium songaricum ferment and preparation technology thereof | |
CN116064685B (en) | Preparation process and application of eurotium cristatum fermented edible traditional Chinese medicine | |
CN105124597A (en) | Preparation method and application of functional monascus-fermented corn bran food | |
CN1142283C (en) | Process for preparing activated polyose by biologic technique and its product | |
KR20020069859A (en) | Method using liquid spawn to reduce growth time for mushroom mycelial grain products | |
KR100844980B1 (en) | Method of producing a Healthy Mulberry Leaf Food by culture of Mushroom Mycelia | |
KR101027964B1 (en) | Process for preparing functional food comprising Goami rice cultivated with mixed pharmaceutical mushrooms | |
KR20100001375A (en) | New method for preparing the low molecular fucoidan from the brown algae fermentation | |
CN104975051A (en) | Method for enriching GABA (gamma-aminobutyric acid) in mulberry leaves | |
KR100496666B1 (en) | method for manufacturing a ferment ginseng using a fungi and functional ginseng products including the ferment ginseng | |
CN109200214A (en) | A kind of highland barley glossy ganoderma fermentation magma and preparation method thereof | |
CN112021563B (en) | Preparation method of sweet potato whole powder rich in free dehydroepiandrosterone | |
CN114431460A (en) | Pure natural edible fungus nutrition powder and preparation method thereof | |
CN100375784C (en) | Complex function type northern Chinese caterpillar fungus and its production method | |
KR20120124877A (en) | The manufacturing method of salicornia herbacea vinegar using unpolished rice | |
KR20020096575A (en) | Process for production of mushroom mycelium highly enriched in trace minerals and product thereof | |
KR100225050B1 (en) | The phelinus linteus composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120629 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |